Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer

In colorectal cancer (CRC) patients, guidelines only recommend measurement of preoperative carcinoembryonic antigen (CEA), although postoperative CEA may be more informative. However, the sensitivity of both preoperative and postoperative CEA in identifying relapse is limited. We studied whether CA1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta oncologica 2020-12, Vol.59 (12), p.1416-1423
Hauptverfasser: Hermunen, Kethe, Soveri, Leena-Maija, Boisen, Mogens Karsbøl, Mustonen, Harri K., Dehlendorff, Christian, Haglund, Caj H., Johansen, Julia Sidenius, Osterlund, Pia
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1423
container_issue 12
container_start_page 1416
container_title Acta oncologica
container_volume 59
creator Hermunen, Kethe
Soveri, Leena-Maija
Boisen, Mogens Karsbøl
Mustonen, Harri K.
Dehlendorff, Christian
Haglund, Caj H.
Johansen, Julia Sidenius
Osterlund, Pia
description In colorectal cancer (CRC) patients, guidelines only recommend measurement of preoperative carcinoembryonic antigen (CEA), although postoperative CEA may be more informative. However, the sensitivity of both preoperative and postoperative CEA in identifying relapse is limited. We studied whether CA19-9, YKL-40, C-reactive protein (CRP) and interleukin (IL)-6 add prognostic information combined with postoperative CEA. This post-hoc analysis included 147 radically resected stage II (n = 38), III (n = 91) and IV (n = 18) CRC patients treated with adjuvant 5-fluorouracil (5-FU)-based therapy in the phase III LIPSYT study (ISRCTN98405441). We collected postoperative blood samples a median of 48 days after surgery. We analysed relapses, sensitivity, positive predictive value (PPV) and disease-free (DFS) and overall survival (OS) by bootstrap, Kaplan-Meier and adjusted Cox-models in the elevated vs. normal biomarker groups. Elevated postoperative CEA associated with impaired DFS (HR 7.23; CI 95% 3.85-13.58), impaired OS (HR 7.16; CI 95% 3.76-13.63), and more relapses (HR 7.9; CI 95% 3.4-18.2); but sensitivity for CEA in finding relapses was only 31% (CI 95% 21-48%). Normal CEA combined with an elevated YKL-40 or elevated CRP showed more relapses (HR for YKL-40 2.13 [CI 95% 1.10-4.13], HR for CRP 3.14 [CI 95% 1.21-8.16]), impaired DFS (HR 2.18 [CI 95% 1.12-4.24] or 3.23 [CI 95% 1.34-7.82]), and impaired OS (2.33 [CI 95% 1.24-4.40] or 2.68 [CI 95% 1.12-6.44]). Elevated CEA combined with a concomitantly elevated CA19-9, YKL-40, CRP or IL-6 showed a respective PPV of 100, 90, 100, and 100%. In radically operated stage II to IV CRC patients who received adjuvant 5-FU-based chemotherapy, a postoperatively elevated CEA alone or in combination with CA19-9, YKL-40, CRP, or IL-6, or a normal CEA combined with an elevated YKL-40 or with an elevated CRP, may indicate patients at high risk of relapse.
doi_str_mv 10.1080/0284186X.2020.1800086
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_0284186X_2020_1800086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2434474398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-19574390a72bc04bcc26e0a3533da23d4aa1b68979287aefb43300cf5d4e8e7a3</originalsourceid><addsrcrecordid>eNp9kctKxDAYhYMoOF4eQcjShdXc2qY7h-INBxRR0FX4m6YabZsxaUd8Cl_Z1NGtq9y-c5KTg9ABJceUSHJCmBRUZo_HjLC4JQkhMttAM5qlNGEse9xEs4lJJmgb7YTwGhHG83SGvm5dGNzSeBjsyuBg_Njhck6LpDjCT9eLRJAjXN7dYuhrfLVIMmx7rF1X2T4qXI8_7PCCy7M5hoCX3j330c9q3IF_Mz7gxnnsjR69N702Py5h9Cu7gnbt1Lp4PMSVhgj4PbTVQBvM_u-4ix7Oz-7Ly2Rxc3FVzheJ5gUZElqkuYgzyFmliai0ZpkhwFPOa2C8FgC0ymSRF0zmYJpKcE6IbtJaGGly4LvocO0b3_w-mjCozgZt2hZ648agmOBCTFfIiKZrVHsXgjeNWnob830qStRUgPorQE0FqN8Cou50rbN9_IUOPpxvazXAZ4zc-JjWBsX_t_gGfWaMig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2434474398</pqid></control><display><type>article</type><title>Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer</title><source>Access via Taylor &amp; Francis</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Hermunen, Kethe ; Soveri, Leena-Maija ; Boisen, Mogens Karsbøl ; Mustonen, Harri K. ; Dehlendorff, Christian ; Haglund, Caj H. ; Johansen, Julia Sidenius ; Osterlund, Pia</creator><creatorcontrib>Hermunen, Kethe ; Soveri, Leena-Maija ; Boisen, Mogens Karsbøl ; Mustonen, Harri K. ; Dehlendorff, Christian ; Haglund, Caj H. ; Johansen, Julia Sidenius ; Osterlund, Pia</creatorcontrib><description>In colorectal cancer (CRC) patients, guidelines only recommend measurement of preoperative carcinoembryonic antigen (CEA), although postoperative CEA may be more informative. However, the sensitivity of both preoperative and postoperative CEA in identifying relapse is limited. We studied whether CA19-9, YKL-40, C-reactive protein (CRP) and interleukin (IL)-6 add prognostic information combined with postoperative CEA. This post-hoc analysis included 147 radically resected stage II (n = 38), III (n = 91) and IV (n = 18) CRC patients treated with adjuvant 5-fluorouracil (5-FU)-based therapy in the phase III LIPSYT study (ISRCTN98405441). We collected postoperative blood samples a median of 48 days after surgery. We analysed relapses, sensitivity, positive predictive value (PPV) and disease-free (DFS) and overall survival (OS) by bootstrap, Kaplan-Meier and adjusted Cox-models in the elevated vs. normal biomarker groups. Elevated postoperative CEA associated with impaired DFS (HR 7.23; CI 95% 3.85-13.58), impaired OS (HR 7.16; CI 95% 3.76-13.63), and more relapses (HR 7.9; CI 95% 3.4-18.2); but sensitivity for CEA in finding relapses was only 31% (CI 95% 21-48%). Normal CEA combined with an elevated YKL-40 or elevated CRP showed more relapses (HR for YKL-40 2.13 [CI 95% 1.10-4.13], HR for CRP 3.14 [CI 95% 1.21-8.16]), impaired DFS (HR 2.18 [CI 95% 1.12-4.24] or 3.23 [CI 95% 1.34-7.82]), and impaired OS (2.33 [CI 95% 1.24-4.40] or 2.68 [CI 95% 1.12-6.44]). Elevated CEA combined with a concomitantly elevated CA19-9, YKL-40, CRP or IL-6 showed a respective PPV of 100, 90, 100, and 100%. In radically operated stage II to IV CRC patients who received adjuvant 5-FU-based chemotherapy, a postoperatively elevated CEA alone or in combination with CA19-9, YKL-40, CRP, or IL-6, or a normal CEA combined with an elevated YKL-40 or with an elevated CRP, may indicate patients at high risk of relapse.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.1080/0284186X.2020.1800086</identifier><language>eng</language><publisher>Taylor &amp; Francis</publisher><ispartof>Acta oncologica, 2020-12, Vol.59 (12), p.1416-1423</ispartof><rights>2020 Acta Oncologica Foundation 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-19574390a72bc04bcc26e0a3533da23d4aa1b68979287aefb43300cf5d4e8e7a3</citedby><cites>FETCH-LOGICAL-c390t-19574390a72bc04bcc26e0a3533da23d4aa1b68979287aefb43300cf5d4e8e7a3</cites><orcidid>0000-0002-7124-3515</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/0284186X.2020.1800086$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/0284186X.2020.1800086$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,59647,60436</link.rule.ids></links><search><creatorcontrib>Hermunen, Kethe</creatorcontrib><creatorcontrib>Soveri, Leena-Maija</creatorcontrib><creatorcontrib>Boisen, Mogens Karsbøl</creatorcontrib><creatorcontrib>Mustonen, Harri K.</creatorcontrib><creatorcontrib>Dehlendorff, Christian</creatorcontrib><creatorcontrib>Haglund, Caj H.</creatorcontrib><creatorcontrib>Johansen, Julia Sidenius</creatorcontrib><creatorcontrib>Osterlund, Pia</creatorcontrib><title>Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer</title><title>Acta oncologica</title><description>In colorectal cancer (CRC) patients, guidelines only recommend measurement of preoperative carcinoembryonic antigen (CEA), although postoperative CEA may be more informative. However, the sensitivity of both preoperative and postoperative CEA in identifying relapse is limited. We studied whether CA19-9, YKL-40, C-reactive protein (CRP) and interleukin (IL)-6 add prognostic information combined with postoperative CEA. This post-hoc analysis included 147 radically resected stage II (n = 38), III (n = 91) and IV (n = 18) CRC patients treated with adjuvant 5-fluorouracil (5-FU)-based therapy in the phase III LIPSYT study (ISRCTN98405441). We collected postoperative blood samples a median of 48 days after surgery. We analysed relapses, sensitivity, positive predictive value (PPV) and disease-free (DFS) and overall survival (OS) by bootstrap, Kaplan-Meier and adjusted Cox-models in the elevated vs. normal biomarker groups. Elevated postoperative CEA associated with impaired DFS (HR 7.23; CI 95% 3.85-13.58), impaired OS (HR 7.16; CI 95% 3.76-13.63), and more relapses (HR 7.9; CI 95% 3.4-18.2); but sensitivity for CEA in finding relapses was only 31% (CI 95% 21-48%). Normal CEA combined with an elevated YKL-40 or elevated CRP showed more relapses (HR for YKL-40 2.13 [CI 95% 1.10-4.13], HR for CRP 3.14 [CI 95% 1.21-8.16]), impaired DFS (HR 2.18 [CI 95% 1.12-4.24] or 3.23 [CI 95% 1.34-7.82]), and impaired OS (2.33 [CI 95% 1.24-4.40] or 2.68 [CI 95% 1.12-6.44]). Elevated CEA combined with a concomitantly elevated CA19-9, YKL-40, CRP or IL-6 showed a respective PPV of 100, 90, 100, and 100%. In radically operated stage II to IV CRC patients who received adjuvant 5-FU-based chemotherapy, a postoperatively elevated CEA alone or in combination with CA19-9, YKL-40, CRP, or IL-6, or a normal CEA combined with an elevated YKL-40 or with an elevated CRP, may indicate patients at high risk of relapse.</description><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kctKxDAYhYMoOF4eQcjShdXc2qY7h-INBxRR0FX4m6YabZsxaUd8Cl_Z1NGtq9y-c5KTg9ABJceUSHJCmBRUZo_HjLC4JQkhMttAM5qlNGEse9xEs4lJJmgb7YTwGhHG83SGvm5dGNzSeBjsyuBg_Njhck6LpDjCT9eLRJAjXN7dYuhrfLVIMmx7rF1X2T4qXI8_7PCCy7M5hoCX3j330c9q3IF_Mz7gxnnsjR69N702Py5h9Cu7gnbt1Lp4PMSVhgj4PbTVQBvM_u-4ix7Oz-7Ly2Rxc3FVzheJ5gUZElqkuYgzyFmliai0ZpkhwFPOa2C8FgC0ymSRF0zmYJpKcE6IbtJaGGly4LvocO0b3_w-mjCozgZt2hZ648agmOBCTFfIiKZrVHsXgjeNWnob830qStRUgPorQE0FqN8Cou50rbN9_IUOPpxvazXAZ4zc-JjWBsX_t_gGfWaMig</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Hermunen, Kethe</creator><creator>Soveri, Leena-Maija</creator><creator>Boisen, Mogens Karsbøl</creator><creator>Mustonen, Harri K.</creator><creator>Dehlendorff, Christian</creator><creator>Haglund, Caj H.</creator><creator>Johansen, Julia Sidenius</creator><creator>Osterlund, Pia</creator><general>Taylor &amp; Francis</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7124-3515</orcidid></search><sort><creationdate>20201201</creationdate><title>Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer</title><author>Hermunen, Kethe ; Soveri, Leena-Maija ; Boisen, Mogens Karsbøl ; Mustonen, Harri K. ; Dehlendorff, Christian ; Haglund, Caj H. ; Johansen, Julia Sidenius ; Osterlund, Pia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-19574390a72bc04bcc26e0a3533da23d4aa1b68979287aefb43300cf5d4e8e7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hermunen, Kethe</creatorcontrib><creatorcontrib>Soveri, Leena-Maija</creatorcontrib><creatorcontrib>Boisen, Mogens Karsbøl</creatorcontrib><creatorcontrib>Mustonen, Harri K.</creatorcontrib><creatorcontrib>Dehlendorff, Christian</creatorcontrib><creatorcontrib>Haglund, Caj H.</creatorcontrib><creatorcontrib>Johansen, Julia Sidenius</creatorcontrib><creatorcontrib>Osterlund, Pia</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hermunen, Kethe</au><au>Soveri, Leena-Maija</au><au>Boisen, Mogens Karsbøl</au><au>Mustonen, Harri K.</au><au>Dehlendorff, Christian</au><au>Haglund, Caj H.</au><au>Johansen, Julia Sidenius</au><au>Osterlund, Pia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer</atitle><jtitle>Acta oncologica</jtitle><date>2020-12-01</date><risdate>2020</risdate><volume>59</volume><issue>12</issue><spage>1416</spage><epage>1423</epage><pages>1416-1423</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><abstract>In colorectal cancer (CRC) patients, guidelines only recommend measurement of preoperative carcinoembryonic antigen (CEA), although postoperative CEA may be more informative. However, the sensitivity of both preoperative and postoperative CEA in identifying relapse is limited. We studied whether CA19-9, YKL-40, C-reactive protein (CRP) and interleukin (IL)-6 add prognostic information combined with postoperative CEA. This post-hoc analysis included 147 radically resected stage II (n = 38), III (n = 91) and IV (n = 18) CRC patients treated with adjuvant 5-fluorouracil (5-FU)-based therapy in the phase III LIPSYT study (ISRCTN98405441). We collected postoperative blood samples a median of 48 days after surgery. We analysed relapses, sensitivity, positive predictive value (PPV) and disease-free (DFS) and overall survival (OS) by bootstrap, Kaplan-Meier and adjusted Cox-models in the elevated vs. normal biomarker groups. Elevated postoperative CEA associated with impaired DFS (HR 7.23; CI 95% 3.85-13.58), impaired OS (HR 7.16; CI 95% 3.76-13.63), and more relapses (HR 7.9; CI 95% 3.4-18.2); but sensitivity for CEA in finding relapses was only 31% (CI 95% 21-48%). Normal CEA combined with an elevated YKL-40 or elevated CRP showed more relapses (HR for YKL-40 2.13 [CI 95% 1.10-4.13], HR for CRP 3.14 [CI 95% 1.21-8.16]), impaired DFS (HR 2.18 [CI 95% 1.12-4.24] or 3.23 [CI 95% 1.34-7.82]), and impaired OS (2.33 [CI 95% 1.24-4.40] or 2.68 [CI 95% 1.12-6.44]). Elevated CEA combined with a concomitantly elevated CA19-9, YKL-40, CRP or IL-6 showed a respective PPV of 100, 90, 100, and 100%. In radically operated stage II to IV CRC patients who received adjuvant 5-FU-based chemotherapy, a postoperatively elevated CEA alone or in combination with CA19-9, YKL-40, CRP, or IL-6, or a normal CEA combined with an elevated YKL-40 or with an elevated CRP, may indicate patients at high risk of relapse.</abstract><pub>Taylor &amp; Francis</pub><doi>10.1080/0284186X.2020.1800086</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-7124-3515</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0284-186X
ispartof Acta oncologica, 2020-12, Vol.59 (12), p.1416-1423
issn 0284-186X
1651-226X
language eng
recordid cdi_crossref_primary_10_1080_0284186X_2020_1800086
source Access via Taylor & Francis; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T08%3A25%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postoperative%20serum%20CA19-9,%20YKL-40,%20CRP%20and%20IL-6%20in%20combination%20with%20CEA%20as%20prognostic%20markers%20for%20recurrence%20and%20survival%20in%20colorectal%20cancer&rft.jtitle=Acta%20oncologica&rft.au=Hermunen,%20Kethe&rft.date=2020-12-01&rft.volume=59&rft.issue=12&rft.spage=1416&rft.epage=1423&rft.pages=1416-1423&rft.issn=0284-186X&rft.eissn=1651-226X&rft_id=info:doi/10.1080/0284186X.2020.1800086&rft_dat=%3Cproquest_cross%3E2434474398%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2434474398&rft_id=info:pmid/&rfr_iscdi=true